Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs provides customers with a wide range of CD147 CAR-related products to support CART projects. Below are some of our CD147 CAR products for customers' reference. You can also search for products you are interested in by searching for the corresponding keywords.
CD147, known as a tumor-associated antigen, is a highly glycosylated transmembrane immunoglobulin that is broadly and specifically expressed in a variety of tumor types, including hepatocellular carcinoma, non-small cell lung cancer, and breast cancer. CD147 is involved in tumorigenesis processes, including tumor cell invasion, metastasis, and angiogenesis. Focusing on these characteristics, CD147 has been proposed as a potential therapeutic target for many cancers.
Associated Diseases
For different targets and project requirements, it is crucial to select the appropriate CAR structure. Leveraged by years of experience in the field of CART, Creative Biolabs offers a variety of effective CAR structural designs to assist our customers in their projects, such as classical CAR designs, and special armored CAR designs.
Fig.1 Schematic diagram of the CD147 CAR construction.1
Anti-CD147 CAR-T Expression Test
CAR expression testing helps us to ensure that the specific CAR-T cells express the appropriate receptors and molecules at the correct levels, which is crucial for their function and survival. We utilize many different approaches (e.g., flow cytometry, western blot, and qPCR) to test CAR expression.
Fig.2 CAR expression test of CD147-CART cells by flow cytometry using anti-protein L antibody.1
Phenotype Analysis of Anti-CD147 CAR-T
To assess the performance of CART cells in response to specific stimuli, we have developed various robust phenotypic analysis services to assist CART development, such as activation test, exhaustion detection, and cell subsets test.
Fig.3 Activation marker test of CD147-CART cells by flow cytometry.1
Anti-CD147 CAR-T Cytokine Release Test
Cytokine release test is a commonly used assay to assess the ability of CAR-T cells to produce and release cytokines in response to specific stimuli. Creative Biolabs is committed to providing various convenient and sensitive cytokine tests for customers to choose from, such as intracellular cytokine flow detection, and multiple cytokine arrays.
Fig.4 Cytokine detection of CD147 CAR-T co-cultured with various target cells by multiple cytokine profiling.1
Anti-CD147 CAR-T In Vitro Cytotoxicity Assay
In vitro tumor cell killing experiments evaluate the target specificity and effectiveness of CART cells against tumor cells, providing relevant data references for in vivo efficacy studies. By utilizing various means, Creative Biolabs offers a variety of effective cytotoxicity testing services to verify the tumor-killing potential of CART cells.
Fig.5 In vitro killing test of anti-CD147 CAR-T cells against different tumor cells at indicated E:T ratio.1
Efficacy Test of Anti-CD147 CAR-T
To further assess the efficacy of CART cells against targeted tumors in vivo, Creative Biolabs offers a comprehensive range of appropriate animal models and in vivo experimental designs to verify the potent anti-tumor activity of CAR-T cells via multiple approaches. Considering the safety of CART therapy in the living organism, we also provide relevant toxicity evaluation services to assist CART development.
CDX Model for CD147 CAR-T
Fig.6 In vivo anti-tumor activity of CD147-CART cells in A549 CDX models. (A) In vivo experimental design diagram of CD147-CART in CDX model. Living imaging (B) and the dynamic measurement curves of tumor volume (C) and mouse weight (D) in A549 CDX models with CD147 CART treatment.1
PDX Model for CD147 CAR-T
Fig.7 In vivo anti-tumor activity of CD147-CART cells in PDX models. (A) In vivo experimental design diagram of CD147-CART in PDX model. The dynamic measurement curves of tumor volume (B) and mouse weight (C) in PDX models with CD147-CART treatment.1
Reference
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-ZP8943 | Anti-CD147 (HPPAT-082-01) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | HPPAT-082-01 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP8944 | Anti-CD147 (HPPAT-082-01) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | HPPAT-082-01 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP8945 | Anti-CD147 (HPPAT-082-02) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | HPPAT-082-02 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP8960 | Anti-CD147 (Ziralimumab) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | Ziralimumab | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP8961 | Anti-CD147 (2.6.1 ) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 2.6.1 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP8962 | Anti-CD147 (2.6.1 ) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 2.6.1 | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP8963 | Anti-CD147 (ABX-RB2) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | ABX-RB2 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP8964 | Anti-CD147 (ABX-RB2) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | ABX-RB2 | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP8967 | Anti-CD147 (C4shlA5) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | C4shlA5 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP8968 | Anti-CD147 (C4shlA5) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | C4shlA5 | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP8969 | Anti-CD147 (C4shlA6) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | C4shlA6 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP8970 | Anti-CD147 (C4shlA6) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | C4shlA6 | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-ZP8971 | Anti-CD147 (C4shlB2) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | C4shlB2 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| XS-0822-YF34 | Anti-Human CD147 (XW-34) h(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-34 | Mouse | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF954 | Anti-Human CD147 (XW-34) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-34 | Mouse | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF1874 | Anti-Human CD147 (XW-34) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-34 | Mouse | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-1122-YF34 | Anti-CD147 KIR CAR (scFv-KIR2DS2-DAP12, XW-34), pCDCAR1 | Human | XW-34 | Mouse | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
| XS-1122-YF954 | Anti-CD147 TCR-ABR (scFv-TCRα, XW-34) CAR Plasmid, pCDCAR1 | Human | XW-34 | Mouse | scFv-TCRα | Lentiviral vector | T Cell | ||
| XS-1122-YF1874 | Anti-CD147 TCR-ABR (scFv-TCRβ, XW-34) CAR Plasmid, pCDCAR1 | Human | XW-34 | Mouse | scFv-TCRβ | Lentiviral vector | T Cell | ||
| XS-1122-YF2794 | Anti-CD147 TCR-ABR (scFv-CD3γ, XW-34) CAR Plasmid, pCDCAR1 | Human | XW-34 | Mouse | scFv-CD3γ | Lentiviral vector | T Cell |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
